Alendronate for bone damage in adults with sickle cell disease
Part of Blood & lymphatic, Bones, joints & muscles, Genetic & congenital clinical trials.
This trial tests if the drug alendronate can help heal bone damage caused by sickle cell disease. It may be an option if you have this bone problem and are between 18 and 80 years old.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have sickle cell disease (any type, confirmed by a blood test).
- You are able to lie still for a bone density scan (DXA).
- If you could become pregnant, you must have a negative urine pregnancy test before starting.
- You have not been in the hospital for any reason in the last 2 weeks.
- You are not currently pregnant or in prison.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if taking zinc supplements can improve bone health in people with sickle cell disease. It's for those with certain types of sickle cell disease (SS or S-Beta zero thalassemia) who are not on chronic transfusions or zinc supplements.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This trial tests early screening and treatment to prevent heart problems in people with sickle cell disease. It focuses on those with high iron levels or heart symptoms, using regular heart imaging to monitor and treat complications early.
This study looks at how carrying the sickle cell trait (not the disease) affects bone density, physical function, and frailty in older African American women. It aims to help understand bone loss risk and prevent fractures.
This early-phase study tests panobinostat, a medicine aimed at reducing sickle-cell problems, in adults with severe disease. It’s mainly looking at safety and whether it can improve blood-related issues that drive pain and complications.
This trial tests a stem cell transplant from a half-matched donor using a strong conditioning regimen and a drug called defibrotide to protect organs. It aims to cure sickle cell disease in patients who have had serious complications like stroke, chest syndrome, or frequent pain episodes.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.